Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2023-04-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2022-0422.pdf |
| _version_ | 1797844885534932992 |
|---|---|
| author | Shang-Chin Huang Chun-Jen Liu |
| author_facet | Shang-Chin Huang Chun-Jen Liu |
| author_sort | Shang-Chin Huang |
| collection | DOAJ |
| description | The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population. |
| first_indexed | 2024-04-09T17:30:42Z |
| format | Article |
| id | doaj.art-b6447da2b4224181aff9b071b16ddbcd |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-04-09T17:30:42Z |
| publishDate | 2023-04-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-b6447da2b4224181aff9b071b16ddbcd2023-04-18T07:21:34ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-04-0129232033110.3350/cmh.2022.04221770Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectivesShang-Chin Huang0Chun-Jen Liu1 Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanThe prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population.http://e-cmh.org/upload/pdf/cmh-2022-0422.pdffatty liverhepatitis b virusnon-alcoholic fatty liver diseasemetabolic syndromehepatocellular carcinoma |
| spellingShingle | Shang-Chin Huang Chun-Jen Liu Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives Clinical and Molecular Hepatology fatty liver hepatitis b virus non-alcoholic fatty liver disease metabolic syndrome hepatocellular carcinoma |
| title | Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives |
| title_full | Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives |
| title_fullStr | Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives |
| title_full_unstemmed | Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives |
| title_short | Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives |
| title_sort | chronic hepatitis b with concurrent metabolic dysfunction associated fatty liver disease challenges and perspectives |
| topic | fatty liver hepatitis b virus non-alcoholic fatty liver disease metabolic syndrome hepatocellular carcinoma |
| url | http://e-cmh.org/upload/pdf/cmh-2022-0422.pdf |
| work_keys_str_mv | AT shangchinhuang chronichepatitisbwithconcurrentmetabolicdysfunctionassociatedfattyliverdiseasechallengesandperspectives AT chunjenliu chronichepatitisbwithconcurrentmetabolicdysfunctionassociatedfattyliverdiseasechallengesandperspectives |